Clinical Trials

Search Trials

For best results, use specific search terms. For example, instead of "brain tumor," try "glioblastoma." You can also contact the Clinical Trials Office at 312-695-1102 for assistance.

A single arm open-label pilot study to investigate the safety and clinical activity of cemiplimab, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with incurable NUT Carcinoma (NC) This study assess the preliminary effect of cemiplimab treatment on survival in patients with recurrent, or advanced NC at 6 months from start of treatment Patients with NUT carcinoma (NC) will be treated with cemiplimab (REGN2810) for up to 96 weeks (32 cycles) or until disease progression. Cemiplimab will be administered intravenously at a dose of 350 mg every three weeks (each cycle is 21 days). This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Eligibility Criteria Must have a histologically confirmed NUT carcinoma that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. ·Participants must be 18 or older This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator Lorch, Jochen Hanns-Martin Location(s) Map it 201 E. Huron St. Chicago, IL ClinicalTrials.gov IdentifierNCT07050186IRB number STU00224031 More Info Keywords NUT carcinoma

A single arm open-label pilot study to investigate the safety and clinical activity of cemiplimab, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with incurable NUT Carcinoma (NC)

This study assess the preliminary effect of cemiplimab treatment on survival in patients with recurrent, or advanced NC at 6 months from start of treatment
Patients with NUT carcinoma (NC) will be treated with cemiplimab (REGN2810) for up to 96 weeks (32 cycles) or until disease progression. Cemiplimab will be administered intravenously at a dose of 350 mg every three weeks (each cycle is 21 days).

This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.

Eligibility Criteria

Must have a histologically confirmed NUT carcinoma that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.
·Participants must be 18 or older

This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.

Principal Investigator

Lorch, Jochen Hanns-Martin

Location(s)

Map it 201 E. Huron St.
Chicago, IL

ClinicalTrials.gov IdentifierNCT07050186IRB number STU00224031

More Info

Keywords NUT carcinoma